News & events.

Our news.

Filter by Category
Filter by Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Event
February 8, 2022
2022

Festival of Biologics USA 2022

News
January 27, 2022
2022

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

News
January 9, 2022
2022

AbCellera’s statement on the neutralization activity of its monoclonal antibody therapies against the Omicron variant of concern

News
December 7, 2021
2021

AbCellera Announces Changes to Its Board of Directors

News
December 3, 2021
2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

News
December 2, 2021
2021

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

News
November 4, 2021
2021

AbCellera Announces Virtual Presentations at Investor Conferences in November

Event
November 4, 2021
2021

PepTalk 2022

Event
November 4, 2021
2021

European Antibody Therapeutics Xchange 2021

News
November 2, 2021
2021

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19